排名前五的靶点	数量

CDPK1(钙依赖蛋白激酶1)	3
MetRS(甲硫氨酰-tRNA合成酶)	2
PDE10A(磷酸二酯酶10A)	2
TAU(微管相关蛋白tau)	2
PDGF(血小板源性生长因子)	1

关联

项与 University of Washington 相关的药物

Varespladib

靶点

sPLA2

作用机制

sPLA2抑制剂

在研机构

University of Washington [+1]

原研机构

Eli Lilly & Co.

在研适应症

蛇咬伤

非在研适应症

急性胸部综合征 [+7]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

[18F]FluorThanatrace

靶点

PARP1

作用机制

PARP1抑制剂 [+1]

在研机构

Abramson Cancer Center [+3]

原研机构

Trevarx Biomedical, Inc.

[+1]

在研适应症

乳腺癌 [+8]

非在研适应症

胶质母细胞瘤 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

AST-302

靶点

HER2 x IGF-1R x IGFBP2

作用机制

HER2拮抗剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

1,916

项与 University of Washington 相关的临床试验

NCT06499740

/ Not yet recruitingN/AIIT

Adapting a Brief Suicide Intervention for Pediatric Primary Care: Enhancing Uptake and Impact

Suicide is a leading cause of death among adolescents in the United States and improving access to high quality just-in-time suicide interventions to reduce risk has important public health implications. Integrating such interventions into routinely accessed settings, such as pediatric primary care, holds promise; however, many clinicians in these settings fail to adequately screen or intervene in youth suicidal thoughts and behaviors, representing a key barrier to reducing suicide. The proposed study is a pre-post quasi-experimental pilot feasibility and preliminary efficacy trial of an adaptation of the SAFETY-Acute suicide prevention intervention implemented in 3 pediatric primary care clinics.

开始日期2026-10-01

申办/合作机构

University of Washington

[+1]

NCT07024953

/ Not yet recruitingN/AIIT

Setting the Agenda: A Pilot Stepped Wedge Cluster Randomized Trial of a Structured Clinical Visit Agenda-Setting Intervention for Rural-Residing People With Advanced Chronic Kidney Disease

The goal of this clinical trial is to learn if a tool with a list of discussion topics, called a structured clinical visit agenda-setting intervention (SAS), works for people with advanced chronic kidney disease (CKD) who receive care at a clinic that serves people who live in rural areas. The SAS is called CKD Topics. The researchers will compare the SAS intervention to usual care (the way clinicians usually practice) to see how well it works for people with advanced CKD. This is a special type of clinical trial called a stepped wedge randomized clinical trial (RCT). In this type of trial, every participant will get to experience both usual care and CKD Topics, but for different amounts of time.
The researchers will learn if doing a clinical trial of CKD Topics is possible (feasible) and get information about how well CKD Topics helps people with advanced CKD shape visit discussions (self-advocacy) in their appointments with their clinicians. The information the researchers collect in this trial will help design a future trial with more participants.
The main questions the researchers aim to answer are:
* Is it possible to conduct this type of study of a SAS intervention? i.e. feasibility
* Does the SAS intervention help people with advanced CKD shape discussions (self-advocacy) with their clinicians? If so, how much? i.e. preliminary efficacy

开始日期2026-09-01

申办/合作机构

Dartmouth-Hitchcock Medical Center

[+3]

NCT06422299

/ Not yet recruitingN/AIIT

Developing and Testing an Online Intervention for Decreasing Alcohol and Cannabis Misuse and Increasing Healthy Relationship Skills Among Young Adult Couples: A Comprehensive Mixed-methods Approach

The goal of this clinical trial is to develop and test a brief online intervention to reduce alcohol and cannabis misuse and improve healthy relationship skills among young adult couples. The main questions it aims to answer are:
* Will the intervention be feasible and acceptable to young adult couples?
* Will the intervention demonstrate initial efficacy in reducing risky substance use and increasing relationship functioning?
Eligible couples will complete a virtual baseline session and be randomized to intervention condition (online intervention with 3-5 weeks of self-paced modules) or control condition (no intervention). Couples will complete two follow-up surveys (post-assessment - approximately 5 weeks after baseline, 3-month). Couples in the control condition will be offered the intervention after 3-month follow-up.
Researchers will compare intervention and control groups to see if there there is a difference between the groups on substance misuse and relationship functioning at post-assessment and 3-month follow-up.

开始日期2026-07-15

申办/合作机构

University of Washington

[+2]

100 项与 University of Washington 相关的临床结果

登录后查看更多信息

0 项与 University of Washington 相关的专利（医药）

登录后查看更多信息

142,103

项与 University of Washington 相关的文献（医药）

2026-04-01·BIOMATERIALS

IFN-γ and TLR agonist co-adjuvants enhance the efficacy of a lipid-PLGA hybrid nanoparticle-based oxycodone vaccine

Article

作者: Hamid, Fatima A ; Rostamizadeh, Kobra ; Marecki, Courtney ; Zhang, Chenming ; Pravetoni, Marco ; Ci, Qiaoqiao ; Qian, Zhen ; Walter, Debra L ; Bian, Yuanzhi ; DeHority, Riley

The ongoing opioid epidemic continues to drive high rates of substance use disorders (SUD), fatal and non fatal overdoses, with oxycodone being one of the most widely misused prescription opioids. Immunopharmacological strategies such as vaccines that induce drug-specific antibodies offer a non-addictive, long-lasting approach to neutralize opioids in the bloodstream and prevent their entry into the central nervous system (CNS). In this study, we evaluated the immunogenicity and efficacy of novel oxycodone vaccine formulations incorporating interferon-γ (IFN-γ), either alone or in combination with toll-like receptor (TLR) agonists, delivered via either conventional hapten-carrier conjugates or lipid-PLGA hybrid nanoparticles (hNPs). All adjuvanted formulations elicited robust anti-oxycodone IgG responses, with IFN-γ + TLR agonist combinations particularly in the hNP platform producing the highest titers and enhanced antibody affinity. Subclass analysis, performed on the hNP-based vaccines, revealed IgG1-dominant responses, with modest IgG2a induction in the TLR-adjuvanted groups, suggesting partial Th1 skewing. Pharmacokinetic studies showed significantly elevated serum and reduced brain oxycodone levels in all vaccinated animals, with the hNP-based vaccine adjuvanted with IFN-γ and R848 providing the most potent CNS protection. In the hot plate assay, all formulations significantly attenuated oxycodone-induced antinociception, with the hNP-based vaccine formulated with IFN-γ and poly I:C producing the greatest reduction. These findings demonstrate that co-delivery of IFN-γ and a TLR agonist via a nanoparticle platform enhances both the magnitude and functional quality of the immune response, supporting further development of this strategy as a promising therapeutic approach for opioid use disorder.

2026-02-01·INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA

Anesthetic management of intrapartum cesarean deliveries with an in-situ epidural catheter during second-stage versus first-stage of labor: a single-center retrospective study (2022–2024)

Article

作者: Delgado, C ; Keasler, P ; Vu, T ; Hajjar, C ; Van Cleve, W

BACKGROUND:

Inadequate anesthesia during cesarean delivery can occur in up to 15% of cases. Second-stage cesarean delivery is associated with increased surgical complexity. We evaluated whether several anesthesia-relevant outcomes differed between first- and second-stage cesareans in patients with an in-situ epidural at our referral institution.

METHODS:

Using a quasi-experimental design, we retrospectively analyzed all intrapartum cesareans with in-situ epidural catheters performed from 2022 to 2024. Maternal, obstetric, neuraxial and intraoperative variables were abstracted. Outcomes were intravenous analgesic or sedative administration, epidural replacement, conversion to general anesthesia, operating-room preparation time, and cesarean duration. After propensity score matching for pre-procedural variables, differences in these outcomes comparing first- and second-stage cesarean cases were examined using effect sizes.

RESULTS:

Among 968 intrapartum cesarean cases, 26% occurred during the second stage of labor. Differences in BMI, rates of labor augmentation, and requirement for epidural top-ups were observed and were mitigated by propensity score matching. Second-stage cesarean cases occurred predominantly due to arrest of stage, with higher rates of uterine atony, postpartum hemorrhage, hysterotomy extension, and longer procedural times. Longer analgesia duration was associated with increased operating room preparation time, cesarean duration, and neuraxial replacement before procedure. Rates of intraoperative intravenous adjunct use and conversion to general anesthesia were comparable across stages and analgesia duration.

CONCLUSIONS:

After propensity score matching, stage of labor at the time of procedure was not associated with increased intravenous adjunct use or general anesthesia conversion for intrapartum cesareans. Neuraxial anesthesia remains a reliable choice for second-stage cesarean delivery when managed proactively, though prolonged analgesia warrants vigilance for catheter replacement before surgery.

2026-02-01·NEURAL NETWORKS

Improving few-shot relation classification with multi-scale hierarchical prototype learning

Article

作者: Peng, Tao ; Liu, Shengyue ; Han, Jiayu ; Cui, Hai ; Liu, Lu ; Han, Ridong ; Bi, Haijia

Few-shot relation classification aims to distinguish different relation classes from extremely limited annotated data. Most existing methods primarily use prototype networks to construct a prototypical representation, classifying the instance by comparing its similarity to each prototype. Despite achieving promising results, the prototypes derived solely from limited support instances are often inaccurate due to constraints in feature extraction capabilities. Moreover, they ignore the different hierarchical levels of relational information, which can provide more effective guidance for classification. In this paper, we propose a novel multi-scale hierarchical prototype (Mario) learning method that captures relational interaction information at three levels: inter-set, inter-class and intra-class, enhancing the model's understanding of global semantic information and helping it distinguish subtle differences between classes. Additionally, we incorporate relational descriptive information to reduce the impact of textual expression diversity, enabling the model to emulate the human cognitive process in understanding variation. Extensive experiments conduct on the FewRel dataset demonstrate the effectiveness of our proposed model. In particular, it achieves accuracy rates of 92.52 %/95.33 %/85.46 %/91.33 % under four common few-shot settings. Notably, in the critical 5-way and 10-way 1-shot settings, it outperforms the strongest baseline by 2.87 % and 4.29 %.

1,154

项与 University of Washington 相关的新闻（医药）

2025-10-29

·PRNewswire

Sparrow BioAcoustics Secures $10 Million to Support Expanding U.S. Deployment of Smartphone-Based Cardiac AI

Sparrow BioAcoustics today announced the closing of a $10 million financing round led by Killick Capital and Klister Credit, with participation from Pelorus VC, 98827 Newfoundland & Labrador Inc., and Brinex Capital. ST. JOHN'S, NL, Oct. 29, 2025 /PRNewswire/ - The new investment supports Sparrow's next phase of growth as hospitals across North America adopt its FDA-cleared Stethophone platform, which is the world's first cardiac AI platform delivering bioacoustic detection of structural and rhythmic heart anomalies directly through a smartphone. "This round ensures we can scale responsibly through this critical phase, supporting hospitals and patients with the same focus on quality and outcomes that brought us here," said Mark Opauszky, CEO of Sparrow BioAcoustics. "It's about maintaining the momentum we've built while continuing to deliver real clinical value where it's needed most." A recent study published in the International Journal of Medical Science and Innovation Research examined the use and clinical accuracy of Sparrow's Stethophone AI at the University of Washington Medical Center, finding it to be highly accurate in the detection of valvular disease and atrial fibrillation. The authors noted "the system's AI potential as a mechanism to revolutionize cardiac screening by employing widely available smartphone technology, ensuring broader access to high-quality cardiovascular assessment across diverse healthcare settings," and highlighted that "improved murmur detection represents a strategic opportunity: earlier identification can lead to increased utilization of confirmatory testing and timely interventions." Stethophone is currently being evaluated at several major clinical sites in the United States and Canada. "In the past year, about 40,000 patients and practitioners have used Stethophone, uncovering thousands of cardiac anomalies that might otherwise have gone unnoticed until later stages of disease," said Dr. Yaroslav Shpak, Chief Medical Officer and co-founder of Sparrow BioAcoustics. "The demand for practical, scalable screening for conditions such as aortic stenosis continues to grow rapidly, and the feedback from clinicians and patients has been overwhelmingly positive." Sparrow has just presented additional updates at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco (October 24–27) and is going to bring Stethophone to the upcoming American Heart Association Scientific Sessions in New Orleans (November 7–10). About Sparrow BioAcoustics: Sparrow BioAcoustics is a Canadian medical technology company pioneering AI Phonoscopy, the digital examination of heart sounds using artificial intelligence. Its flagship product, Stethophone, transforms ordinary smartphones into medical-grade cardiac assessment tools capable of detecting murmurs and other signs of heart disease without external hardware. By combining clinical accuracy with universal accessibility, Sparrow aims to close the gap in early cardiac detection and empower clinicians and individuals with actionable insights that improve outcomes and reduce the burden of undiagnosed heart disease. SOURCE Sparrow BioAcoustics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AHA会议

2025-10-29

·RNAScript

韩国公司Chaperone、MMV 和 Nanomab 合作共同开发下一代 mRNA-Nanomab 疟疾疫苗

2025年10月29日，Chaperone公司宣布，与瑞士非营利组织疟疾药物研发联盟（MMV）达成战略研究合作，共同开发基于纳米抗体的长效抗疟疾药物。此次合作源于MMV对Chaperone公司纳米抗体技术突破性创新平台的认可。该项目旨在通过将 Chaperone 专有的 NanoMab 平台与纳米抗体的分子简单性以及信使核糖核酸(mRNA) 技术的高效递送能力相结合，开发一种可以快速、大规模生产并向全球（包括发展中国家）供应的产品。双方正共同致力于设计能够同时靶向多种疟原虫抗原，而不仅仅是单一抗原的纳米分子。预计这将对疟疾生命周期的各个阶段产生同步治疗效果。MMV是一家瑞士非营利组织，致力于研发一系列可及性强的新型疟疾治疗、预防和根除药物。自1999年成立以来，MMV一直致力于解决研究、开发和可及性方面的关键缺口，率先扩大现有抗疟药物的适用范围，并推动新药创新。Chaperone将利用MMV的全球网络、专业知识和资源，开发一种适用于发展中国家的单剂量、易于储存的基于mRNA的纳米单克隆抗体被动疫苗。MMV计划利用各种非稀释性金融资源资助战略研究，积极支持候选化合物的临床进入和商业化。Chaperone公司的一位负责人表示：“作为首尔国立大学科技创业公司的衍生企业，获得像MMV这样的全球健康组织的支持，不仅对推进研发至关重要，而且意义重大，因为它使我们能够在不稀释股权的情况下获得资金。” 他补充道：“此次合作是一个转折点，将帮助我们公司在传染病领域的纳米抗体解决方案方面跃升为全球领导者。”与此同时，Chaperone 的主要纳米单克隆抗体项目是基于 mRNA 的 PD-L1 靶点，该项目已进入临床前阶段，并已成功实现体内表达和治疗性血药浓度。为促进mRNA治疗领域的合作交流，我们组建了专业的mRNA行业交流群，目前院校、企事业单位的各路精英已纷纷加入，如果您也想加入交流学习，不要犹豫哦~ 长按下方二维码，添加主编微信进群。由于申请人数较多，添加微信时请备注：院校/企事业单位名称—专业/职务—姓名。如果您是PI/教授/研发骨干/主管及以上职务，还请注明。 2025年10月30日晚，RNAScript将首次携手IGC 2025细胞及衍生物研发与产业化大会，在广州朗豪酒店附近举办「RNAScript粉丝答谢晚宴」，诚邀长期关注RNAScript的朋友、行业专家与新伙伴，共赴一场久违的线下相聚。往期推荐牛津大学团队打造线性无帽mRNA，翻译效率提升7.6倍！下一代mRNA疫苗来了！华盛顿大学及斯坦福团队开发“体内自组装纳米工厂”，中和抗体提升28倍！无需递送载体！谭蔚泓院士团队靶向性适配体嵌合circRNA疫苗公布首次临床试验结果 16.4亿美元！国产体内CAR-T授权MNC，股价暴涨100% 克服肝富集难题！上海交大章雪晴团队计算机辅助开发无胆固醇三组分LNP 26只健康小鼠诞生！PNAS最新重磅：美日团队mRNA疗法攻克无精症脾脏表达提升4.5倍！康奈尔大学江绍毅团队开发脾脏靶向三组分LNP 15亿美金！BMS收购Orbital环状RNA体内CAR-T及独家RNA平台陈学思院士团队ACS Nano：调控磷脂酰聚合物含量，实现器官选择性mRNA递送！有望攻克“超级细菌”？南方科技大学开发金黄色葡萄球菌五价mRNA鸡尾酒疗法张锋领导Aera Therapeutics体内CAR-T临床前数据首公开，将于2026年进入临床从疫苗到妇科：Penn 团队探索mRNA-LNP治疗重度月经过多新途径关注我们聚焦mRNA治疗领域行业发展

疫苗信使RNA

2025-10-29

·生物世界

撰文丨王聪编辑丨王多鱼排版丨水成文信号转导，即细胞感知并响应其环境的过程，这对于生命至关重要。在这个过程中，钙离子（Ca²⁺）是关键角色之一，它们驱动可兴奋细胞的电活动，并调节诸如肌肉收缩、心跳和神经递质释放等多样化的信号事件。细胞表面的被称为钙离子通道（Calcium Channels）的特殊蛋白质，使细胞能够控制 Ca²⁺ 的流入，即使其周围存在较高浓度的钠离子（Na⁺）亦是如此。传统的离子通道研究，主要依赖于对天然离子通道蛋白的突变、结构比对或片段拼接，从而推测其结构与功能的关系，然而，这些方法难以真正重现离子通道的离子选择性。在人工智能（AI）技术的帮助下，我们能否从头设计出一个具有类似离子选择性通过能力的全新离子通道蛋白？ 2025 年 10 月 22 日，诺贝尔奖得主、华盛顿大学 David Baker 教授团队（刘禹来博士为第一作者）在 Nature 期刊发表了题为：Bottom-up design of Ca²⁺ channels from defined selectivity filter geometry 的研究论文。该研究首次使用人工智能（AI）从头设计（de novo design）了全新的钙离子通道，该研究由刘禹来博士领导，这项研究表明，即使是那些只部分为我们所理解的复杂生化功能，如今也能借助 AI 从第一性原理出发进行构建。根本性挑战天然钙离子通道已被改造为研究工具，但这些经过修饰的蛋白分子很脆弱，因而难以操作。而创造出更简单且能实现精准离子选择性的离子通道，一直是一项重大挑战。 David Baker 教授论文通讯作者 David Baker 教授表示，生化学家研究离子通道已有数十年之久，但对其工作原理的争论也几乎持续了同样长的时间。我们着手构建新版本的离子通道，以便研究人员能够精准控制细胞信号转导。由内而外构建研究团队使用他们之前开发的蛋白质设计 AI 算法 RFdiffusion 来构建钙离子通道，从离子选择性过滤区（ion selectivity filter）这一关键结构入手——该结构允许 Ca²⁺ 通过，但同时阻挡 Na⁺ 等类似离子。随后，他们以该结构为基础向外构建支撑性蛋白质结构。与组成蛋白质数据库中大多数已知结构的水溶性蛋白质不同，离子通道在脂质膜内发挥作用，并采用不同的结构折叠方式和功能机制。研究团队必须调整其设计工具，以生成包含孔道的跨膜蛋白结构及氨基酸序列，确保这些结构能可靠折叠为功能性跨膜离子通道蛋白。刘禹来博士论文第一作者刘禹来博士表示，通过设计能够精确控制的离子通道，我们希望以全新的方式研究并最终实现操控细胞行为。验证新通道研究团队首先在人 HEK293T 细胞中筛选出了具有二价离子通透性的候选离子通道。然而，在昆虫细胞中生成了这些离子通道，并采用膜片钳电生理学（评估离子通道功能的黄金标准）进行研究。结果显示，多种设计的钙离子通道均能按预期实现 Ca²⁺ 的选择性转导，其 Ca²⁺ 传输电流强度约为 Na⁺ 的 5 倍。冷冻电镜（cryo-EM）结构解析显示，其中一个功能性通道（CalC6_3）的结构组装与计算设计模型几乎完全吻合，达到了原子级精度（RMSD ≈ 1 Å）。选择性过滤区几何形状和功能的确定对神经科学等领域的启示研究团队设想，将这一设计流程应用于探索离子选择性背后的普遍物理原理，尤其是用于创造自然界中不存在的金属离子通道。这些努力可能会加深对离子如何通过嵌入膜中的蛋白质，以及此类机制如何支持诸如大脑信号转导和免疫细胞激活等复杂过程的理解。这些从头设计的合成离子通道可作为新的研究工具，从神经科学研究实验到心脏生物学模型以及合成信号回路等方面均有应用。从头设计阴离子通道 2025 年 10 月 16 日，西湖大学生命科学学院卢培龙团队（卢培龙曾在 David Baker 实验室进行博士后研究）等，在 Cell 期刊发表题为：De novo designed voltage-gated anion channels suppress neuron firing 的研究论文。该研究首次实现了电压门控阴离子通道的精确从头设计。该人工通道的离子选择机制与电压响应机制均不同于天然离子通道。研究通道通过生化分析、冷冻电镜结构解析、膜片钳电生理记录及分子动力学模拟，全面验证了其结构与功能，并在小鼠模型中证实其可有效抑制神经元电活动。该成果不仅表明科学家已具备从头设计具有“动态开关”功能的跨膜蛋白的能力，更证明此类人工蛋白可在活体动物中发挥生理作用，标志着 AI 驱动的生物分子设计向实际应用迈出了关键一步。论文链接： 1. https://www.nature.com/articles/s41586-025-09646-z 2. https://www.cell.com/cell/abstract/S0092-8674(25)01091-8 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

100 项与 University of Washington 相关的药物交易

登录后查看更多信息

100 项与 University of Washington 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年11月08日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

EP-301 ( HER2 )	胃癌更多	临床2期
STEMVAC(EpiThany) ( CDH3 x ENG x MDM2 x SOX2 x Yb-1 )	转移性三阴性乳腺癌更多	临床2期
[18F]FluorThanatrace ( PARP1 )	转移性乳腺癌更多	临床1/2期
Lopinavir/Ritonavir/Tenofovir ( HIV-1 protease x RT )	HIV感染更多	临床1期
PfGAP3KO ( PfPMX )	疟疾更多	临床1期